ArticleMaterials today. Bio2026
Spatiotemporally controlled ferritin-targeting PROTAC nanoplatform for visualized manipulation of endogenous "Iron pool" in pancreatic cancer therapy.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A Dual GSH/ROS-Functional NIR Fluorescent Platform for Synergistic Photodynamic Therapy and Radiosensitization in Nasopharyngeal Carcinoma.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Ferroptosis-Based Nanotherapy for Pancreatic Ductal Adenocarcinoma Through Glutathione Depletion and Iron Accumulation.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer is a highly malignant tumor with limited response to current therapies. Ferroptosis, as a novel approach in cancer treatment, holds great promise for addressing tumors resistant to conventional treatments. While the introduction of adequate exogenous iron can trigger ferroptosis and be used for magnetic resonance imaging (MRI), the clinical application prospects are hindered by the use of toxic-dose iron. Here, we develop a ferritin-targeting proteolysis targeting chimeras (PROTAC) nanoplatform that can spatiotemporally mobilize intracellular stores of endogenous "Iron Pool", which is composed of an upconversion nanoparticle core, a photosensitizer, a ferritin-targeting PROTAC (termed dFer) linked with a reactive oxygen species (ROS)-cleavable segment, and a pancreatic cancer-targeting peptide. The activity of dFer is initially dormant but can be turned on by ROS generated from the photosensitizer upon near-infrared photoirradiation. Then the activated dFer recognizes and degrades ferritin by redirecting the ubiquitin-proteasome system, leading to a sustained elevation in intracellular iron levels, which can be dynamically monitored in real-time by MRI
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.